Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome
ConditionIrritable Bowel Syndrome (IBS)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorBeijing Tiantan Hospital
About this trial
To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).
Eligibility criteria
Qualifiers
Age range: 18-70 years old;
According to the Rome IV diagnostic criteria for IBS, the screening result is positive;
Mild to moderate IBS patients assessed based on the IBS-SSS.
Disqualifiers
Concurrent gastrointestinal conditions presenting with symptoms potentially overlapping with those of IBS, significant medical comorbidities;
Severe mental disorders associated with marked personality disturbances, active suicidal thoughts or any self harm episodes within the preceding 12 months;
Current or intended pregnancy or lactation;
Cognitive impairment;
Trial design
Treatments tested in this trial
- The pregabalin group
- Routine Treatment
Treatment groups
258 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Hengshui People's Hospital
Collaborator
Hebei Medical University Third Hospital
Collaborator
Beijing Jianjia Rehabilitation Hospital
Collaborator
Source ClinicalTrials.gov